Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cholesterol patents



      

This page is updated frequently with new Cholesterol-related patent applications.




Date/App# patent app List of recent Cholesterol-related patents
02/04/16
20160032014 
 Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 patent thumbnailnew patent Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inhibiting pcsk9 binding to ldlr and having increased ph sensitivity, improved binding affinity and/or increased in vivos half life. In embodiments, the antigen binding proteins specifically bind pcsk9 and have increased ph sensitivity, improved binding affinity and/or increased in vivos half life.
Amgen Inc.


02/04/16
20160031951 
 Peptides having reduced toxicity that stimulate cholesterol efflux patent thumbnailnew patent Peptides having reduced toxicity that stimulate cholesterol efflux
The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., apo ai and apo e), and having high selectivity for abca1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses.
The Regents Of The University Of California


02/04/16
20160031935 
 Small molecule modulators of pcsk9 and methods of use thereof patent thumbnailnew patent Small molecule modulators of pcsk9 and methods of use thereof
A compound of formula (i): or a pharmaceutically acceptable salt, hydrate, solvate, or racemic mixture or stereoisomer thereof, and methods for preventing or treating an ldl-cholesterol-related disease or disorder using such compound(s), and kits and compositions comprising such compound(s).. .
Amorchem Holdings Inc.


02/04/16
20160030562 
 Methods to enhance cancer treatment patent thumbnailnew patent Methods to enhance cancer treatment
Herein are provided methods for reducing or eliminating cancer in a patient in need of cancer treatment, by providing cholesterol deprivation therapy (cdt) in conjunction with antibodies directed against cholesterol-deprived tumor cells. Further provided are methods of enhancing the efficacy of other cancer treatments, by administering cdt and antibodies directed against cholesterol-deprived tumor cells, in combination with additional anti-cancer therapies..
International Business Machines Corporation


01/28/16
20160024554 
 Rapid, low-sample-volume cholesterol and triglyceride assays patent thumbnailRapid, low-sample-volume cholesterol and triglyceride assays
Reagents, assays, methods, kits, devices, and systems for rapid measurement of cholesterol and cholesterol sub-fractions from a blood sample are provided. Total cholesterol, low density lipoprotein cholesterol, and high density lipoprotein cholesterol can be measured in a single assay using kinetic measurements, under conditions in which cholesterol sub-species are converted to a detectable product at distinct rates.
Theranos, Inc.


01/28/16
20160024173 
 Non-hemolytic llo fusion proteins and methods of utilizing same patent thumbnailNon-hemolytic llo fusion proteins and methods of utilizing same
The present invention provides recombinant proteins or peptides comprising a mutated listeriolysin o (llo) protein or fragment thereof, comprising a substitution or internal deletion of the cholesterol-binding domain or a portion thereof, fusion proteins or peptides comprising same, nucleotide molecules encoding same, and vaccine vectors comprising or encoding same. The present invention also provides methods of utilizing recombinant proteins, peptides, nucleotide molecules, and vaccine vectors of the present invention to induce an immune response to a peptide of interest..
Advaxis, Inc.


01/28/16
20160024063 
 Novel 3-(4(benzyloxy)phenyl)hex-4-inoic acid derivative,  preparing same and pharmaceutical composition for preventing and treating metabolic disease including same as effective ingredient patent thumbnailNovel 3-(4(benzyloxy)phenyl)hex-4-inoic acid derivative, preparing same and pharmaceutical composition for preventing and treating metabolic disease including same as effective ingredient
The present invention relates to a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient for the prevention and treatment of metabolic disease. The novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention has excellent activities of activating gpr40 protein and promoting insulin secretion accordingly but has no toxicity when co-administered with other drugs.
Hyundai Pharm Co., Ltd


01/28/16
20160022768 
 Reconstituted high density lipoprotein formulation and production method thereof patent thumbnailReconstituted high density lipoprotein formulation and production method thereof
A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as apoai or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/l and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75.
Csl Limited


01/28/16
20160022701 
 Neuroactive steroids, compositions, and uses thereof patent thumbnailNeuroactive steroids, compositions, and uses thereof
Provided are methods of evaluating or treating a patient, e.g., a patient having a disorder described herein, comprising: a) optionally, acquiring a patient sample; b) acquiring an evaluation of and/or evaluating the sample for an alteration in the level s24(s)-hydroxycholesterol compared to a reference standard.. .
Sage Therapeutics, Inc.


01/21/16
20160015775 
 Lipopeptides for use in treating liver diseases and cardiovascular diseases patent thumbnailLipopeptides for use in treating liver diseases and cardiovascular diseases
The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and/or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and/or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the ntcp-mediated transport of test compound(s).
Ruprecht-karls-universitÄt Heidelberg


01/21/16
20160015673 

Method for lowering cholesterol


The present invention relates to the diagnosis, risk assessment, prevention, and treatment of senile dementia of the alzheimer's type (sdat). More specifically the present invention relates to the measurement of ethanolamine phospholipids in human serum.
Phenomenome Discoveries Inc.


01/21/16
20160015050 

Vegetable oil composition containing palm mid-fraction fat and reducing plasma cholesterol


A method and composition for reducing the cholesterolemic effect in mammals of ingesting a blended nutritional fat composition containing a palm mid-fraction (pmf) hardstock fat combined with an unsaturated vegetable oil. The composition is solid or semi-solid at 20° c.
Brandeis University


01/14/16
20160010088 

Method for inhibiting tumor growth through rna-interference using liposomally associated cdc20 sirna


Liposomal compositions comprising of liposomes of guanidinylated cationic amphiphiles as the main lipid and cholesterol/1,2-dioleoyl-sn-glycero-3-phosphocholine (dopc)/aminopropyl polyethyleneglycol carbamyl-distearoylphosphatidyl-ethanolamine (dspe-peg-nh2) as co-lipids are described. These liposomal compositions containing encapsulated or electrostatically complexed therapeutic small interfering rnas (sirnas) against cdc20, a key cell cycle regulator, inhibit solid tumor growth and melanoma tumor growth on lung in c57bl/6j mice..
Council Of Scientific & Industrial Research


01/14/16
20160009748 

Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism


The invention relates to plasminogen activator-1 (pai-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated pai-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated pai-1, cholesterol, or lipid levels..
Eastern Michigan University


01/14/16
20160008300 

Compositions and methods for nutritional supplementation


Some embodiments herein are directed to a nutritional supplement composition including effective amounts of coenzyme q10, fish oil, vitamin d and a pharmaceutically acceptable excipient. Some embodiments describe a method of promoting nutritional health comprising administering a nutritional supplement composition including coenzyme q10, fish oil, vitamin d and a pharmaceutically acceptable excipient to a subject in need thereof.

01/07/16
20160002255 

Antidiabetic bicyclic compounds


Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.


01/07/16
20160002224 

Novel indole derivatives useful as anti-diabetic agents


Novel compounds of the structural formula (i) are activators of amp-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the ampk-activated protein kinase. The compounds of the present invention may be useful in the treatment of type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension..
Merck Sharp & Dohme Corp.


12/31/15
20150377913 

Device and determination of an analyte in blood


A sample acquiring device, an apparatus and a method for spectrophotometric measurement of high density lipoprotein (hdl) and at least one of total cholesterol (tc), triglycerides (tg) and glucose (fpg).. .
Hemocue Ab


12/31/15
20150377902 

Serological methods and diagnostic tests for syphilis antibodies


A method of detecting antibodies to syphilis antigens includes providing a syphilis detection kit having a screening solid-phase platform with a screening portion coated with non-treponemal syphilis antigens. The screening portion is fabricated by initially dissolving cholesterol in an organic solvent and further diluting the dissolved cholesterol in an ethanol solution comprising cardiolipin and lecithin to form an antigen solution, permitting the antigen solution to evaporate at the screening portion and at least partially coating the screening portion with an antigen coating, and stabilizing the antigen coating into a syphilis antigen complex by overcoating the antigen coating with an overcoat solution comprising an inert protein..
Awareness Technology Inc.


12/31/15
20150376139 

Anti-pcsk9 compounds and methods for the treatment and/or prevention of cardiovascular diseases


Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (pcsk9), and methods of using these modulators to reduce ldl-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (cvd), including treatment of hypercholesterolemia.. .
Shifa Biomedical Corporation


12/31/15
20150376123 

Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient


A biguanide derivative compound with n4-n5 substitution, which is represented by formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of ampk and inhibition of cancer cell proliferation in a low dose, compared with conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc..
Hanall Biopharma Co., Ltd.


12/31/15
20150374783 

Products and methods using soy peptides to lower total and ldl cholesterol levels


Controlled studies demonstrate that products and related methods using soy related peptides lower total and ldl cholesterol levels in individuals. In one exemplary embodiment of the present disclosure, a product containing an effective amount of lunasin peptides that lowers cholesterol levels in an individual that consumes the lunasin peptides is provided.
Soy Labs, Llc


12/31/15
20150374710 

Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds and methods of using the same in the treatemnt and/or prevention of cardiovascular diseases


Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (pcsk9), as well as therapeutic methods for use of such compounds to reduce ldl-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (cvd), including treatment of hypercholesterolemia. Examples of compounds include thiadiazole, isoxazole, 1,2,4-triazole, thiazole, indole, pyrazole, and pyrrolinone derivatives..
Shifa Biomedical Corporation


12/24/15
20150368641 

Methods to screen compounds for regulating usf1 activity and methods and compounds to treat cardiometabolic and lipid pathologies


The deficiency of usf1 confers a remarkable number of clinically relevant beneficial metabolic effects in mice via activation of brown adipose tissue. The usf1 deficient mice have high serum hdl-cholesterol and low triglyceride levels, a beneficial lipid profile opposite to that of human metabolic syndrome.
Terveyden Ja Hyvinvoinnin Laitos (thl)


12/24/15
20150366824 

Induction of estrogen receptor beta by cholesterol biosynthesis inhibitors and methods of treatment of cancer


Disclosed herein are methods and compositions related to the discovery that cholesterol inhibitors induce the anti-proliferative protein, estrogen receptor beta (erβ), in both erα-positive and erα-negative breast cancer cell lines, including triple negative cells.. .
The Curators Of The University Of Missouri


12/17/15
20150361434 

Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery


The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver.
Sirna Therapeutics, Inc.


12/17/15
20150359824 

Improved omega-3 food supplement based on marine oil


A food supplement omega 3 based on marine oils (extracted from fish, fish byproducts, mollusks, krill, algae, microalgae) to fight against hypercholesterolemia and lipoprotein disruption leading to atherosclerosis and so to cardiovascular diseases. Optimization of lipid prevention score (lps) of at least one food supplement omega 3 by adding either high or low lps oil (vegetable and/or marine) according to the lps of the omega 3 based marine oils.

12/10/15
20150353980 

Preparation of 7-dehydrocholesterol and/or the biosynthetic intermediates and/or secondary products thereof in transgenic organisms


The present invention relates to a method for preparing 7-dehydrocholesterol and/or the biosynthetic intermediates and/or secondary products thereof by culturing organisms, in particular yeasts. Furthermore, the invention relates to the preparation of the nucleic acid constructs required for preparing the genetically modified organisms and to said genetically modified organisms, in particular yeasts, themselves..
Organobalance Gmbh


12/10/15
20150352139 

Combination of anticholesterolemic fiber


The present invention relates to fiber compositions comprising fiber derived from onion and soluble fiber. Additionally, the invention relates to food products comprising said fiber compositions.
Universitat De Lleida


12/03/15
20150344540 

Novel glp-1 receptor agonists with cholesterol efflux activity


The present invention provides novel glucagon-like protein-1 (glp-1) receptor agonist compounds that promote cholesterol efflux. The abca1-mediated cholesterol efflux present invention also provides compositions comprising the novel glucagon-like protein-1(glp-1) receptor agonist compounds, and relates to the use of said compounds in therapy, to methods of treatment comprising administration of said compounds to patients, and to the use of said compounds in the manufacture of medicaments..
Novo Nordisk A/s


12/03/15
20150344455 

Compounds, compositions and methods useful for cholesterol mobilization


The invention relates to classes of pharmaceutically-active heterocyclic compounds and pharmaceutically acceptable salts, and hydrates thereof, and compositions comprising the same. The invention also relates to methods for treating or preventing a disease or disorder, which comprises administering a therapeutically or prophylactically effective amount a compound described herein..
Cerenis Therapeutics Holding Sa


12/03/15
20150344430 

Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)


The invention relates to new methods of modulating cholesterol by inhibiting proprotein convertase subtilisin/kexin type 9 (pcsk9) with fatty acid derivatives; and new methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid derivative. The present invention is also directed to fatty acid bioative derivatives and their use in the treatment of metabolic diseases..
Catabasis Pharmacauticals, Iinc.


12/03/15
20150344389 

Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses


The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, syndrome x, thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
Esperion Therapeutics, Inc.


12/03/15
20150344388 

Hydroxyl compounds and compositions for cholesterol management and related uses


The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., syndrome x), thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
Esperion Therapeutics, Inc.


12/03/15
20150342931 

Spirocyclic cetp inhibitors


Compounds having the structure of formula (i), including pharmaceutically acceptable salts of the compounds, are cetp inhibitors and may be useful for raising hdl-cholesterol and reducing ldl-cholesterol in human patients and for treating or preventing atherosclerosis. The chemical compounds that are disclosed cholesterol ester transfer protein (cetp) and are expected to have utility in raising hdl-c, lowering ldl-c, and in the treatment and prevention of atherosclerosis..
Merck Sharp & Dohme Corp.


12/03/15
20150342240 

Nutritional walnut-based compositions


A high nutrition food spread providing walnut-based compositions are disclosed. The spreads have desirable taste and consistency characteristics as well as palatability.

11/26/15
20150337362 

Method for the specific isolation of nucleic acids of interest


A method and diagnostic kit for selective isolation of microorganisms of interest and/or nucleic acids of interest including: a) bringing a liquid biological sample into contact with a saponin formulation to destabilize untargeted elements within the liquid biological sample, b) inducing osmotic shock of the untargeted elements to specifically lyse the untargeted elements, c) adding a solution of at least one enzyme capable of lysing free nucleic acids derived from the untargeted elements lysed in solution in the sample, and d) selectively obtaining the microorganisms of interest or the nucleic acids of interest. A precipitant of the unlysed microorganisms of interest may be optionally added in solution.
Biomerieux


11/26/15
20150336884 

Novel synthetic antioxidants and their uses


The present invention relates to synthetic organic antioxidants of small molecules. The novel dithiol-containing compounds in this invention possess strongest possible capability as both scavenger for free radicals and antioxidant.

11/26/15
20150335615 

Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation


A composition for treating high cholesterol, including synergistically effective amounts of a cholesterol-lowering agent and a lipid metabolism-altering compound chosen from a non-absorbable sugar, a compound that converts nh3 to nh4+, a hydrogen-generating compound, and combinations thereof. A composition for treating high cholesterol, including synergistically effective amounts of a statin chosen from atorvastatin, cerivastatin, fluvastain, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin, and lactulose.

11/19/15
20150328276 

Medical formulation for treating hypercholesterolemia


The present invention relates to a medical formulation comprising: cinnamomum zeylanicum; pinus pinaster; extract of a plant belonging to the saccharum genus; monascus purpureus; taraxacum officinale; camellia sinensis; vitamin b3; alpha tocopherol; coenzyme q10; fish oil comprising eicosapentaenoic acid and docosahexanoic acid; beta-glucan; and/or cholecalciferol. The invention also relates to the medical formulation as a medicament, and especially for treating hypercholesterolemia..

11/19/15
20150328184 

Compositions and methods for glycemic control of subjects with impaired fasting glucose


Compositions and methods for providing anti-diabetic and anti-hyperlipidemia benefits to diabetic subjects currently on medication but not meeting recommended targets for blood glucose, hba1c, blood pressure and total cholesterol.. .
Kgk Synergize, Inc.


11/19/15
20150328142 

Sublingual administration of statins


The invention provides a pharmaceutical composition for the transmucosal delivery of a statin, said composition comprising a statin and a carrier in which said statin is soluble or forms a suspension or emulsion. The invention also provides a pharmaceutical composition comprising a statin for use in inhibiting cholesterol synthesis in vivo, where in said use said composition is delivered by the transmucosal route..
Londonpharma Ltd.


11/12/15
20150322627 

Process for refining chemicals from pulp and paper mill wastewaters


A process for isolating at least one target compound, such as manool, geranyl linalool, ethyl guaiacol, eugenol, veratraldehyde, squalene, terpin, cholesterol, beta-sitosterol, campesterol, stigmasterol, stigmastenol and dehydroabietic acid, from biomass, the process including steps of: obtaining a condensate from a recovery evaporator, a reverse osmosis retentate of a condensate of a pulp and paper mill, or both, the condensate, retentate or both being substantially free of higher molecular weight (approximately >1000 da) cellulose and/or lignin and/or lignin-derived material; optionally ph adjusting and filtering the condensate to collect insoluble material; extracting the condensate, the collected insoluble material, or both, with solid phase extraction (spe), liquid-liquid extraction or solid-liquid extraction to produce an extract containing the at least one target compound; and optionally purifying the extract containing the at least one target compound by thermal fractionation, chromatographic separation, recrystallization ion exchange, chelation, adsorption/desorption, lyophilization and sublimation or combinations thereof. The method is particularly useful for isolating the target compounds from wastewaters produced in a kraft pulp and paper mill, especially from recovery evaporator condensates produced during the treatment of black liquor..
Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Environment


11/12/15
20150322032 

Statins of omega-3 polyunsaturated acids for treating hypercholesterolemia


The present invention relates to novel statin derivatives of omega-3 fatty acids, and their use in treating hypercholesterolemia, obesity, hypertriglyceridemia, cardiovascular diseases, and metabolic diseases, and alzheimer's disease.. .
Jiva Pharma, Inc.


11/12/15
20150322023 

Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors


The present invention provides biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds, isomers thereof, or pharmaceutically acceptable salts. The compounds of the invention show a cetp inhibitory effect that increases hdl-cholesterol levels and reduces ldl-cholesterol levels.
Chong Kun Dang Pharmaceutical Corp.


11/12/15
20150320769 

Sulfated-oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation


Methods and compositions for the prevention and treatment of liver damage or disease in a subject in need thereof are provided. The methods involve providing the sulfated oxysterol 25-hydroxycholesterol-3-sulfate (25hc3s) to the subject e.g.
Virginia Commonwealth University


11/12/15
20150320724 

Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor


Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.. .
Merck Sharp & Dohme Corp.


11/12/15
20150320064 

Creamy yogurt base


This creamy yogurt base provides a base with similar appearance, texture, and taste to cream cheese and sour cream products, but contains less calories, fat, and cholesterol while providing a similar mouth feel associated with consuming these full fat products. Additionally, this product can replace common fats used in cooking, baking, and frozen systems.

11/05/15
20150315621 

One-pot fermentation process for simvastatin production


Simvastatin is a drug used in treatment of hypercholesterolemia because of its inhibitory activities towards cholesterol biosynthesis. The technology described herein is a novel method of biosynthesizing simvastatin directly from an engineered microbial host (such as saccharomyces cerevisiae) using an engineered biosynthetic pathway.
The Regents Of The University Of California


11/05/15
20150315584 

Compositions and methods for silencing apolipoprotein c-iii expression


The present invention provides compositions comprising therapeutic nucleic acids such as interfering rna that target apolipoprotein c-iii (apoc3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for the treatment of lipid diseases or disorders such as atherosclerosis or a dyslipidemia such as hypertriglyceridemia or hypercholesterolemia).. .
Protiva Biotherapeutics, Inc.


11/05/15
20150315178 

Plasminogen activator inhibitor-1 inhibitors and methods of use thereof


The invention relates to plasminogen activator-1 (pai-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated pai-1. The invention includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated pai-1, cholesterol, or lipid levels..
Eastern Michigan University


11/05/15
20150315112 

Novel low molecular weight cationic lipids for oligonucleotide delivery


The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver.
Sirna Therapeutics, Inc.


10/29/15
20150307508 

Application of an alkaloid derived from a chinese herbal for treatment of cancer by inhibiting cholesterol synthesis and fatty acid oxidation


The present invention discloses a method of treating gefitinib-resistant non-small-cell lung cancer, comprising administering an effective amount of an alkaloid. A pharmaceutical composition comprising an alkaloid admixed with a pharmaceutical carrier for treating gefitinib-resistant non-small-cell lung cancer is also disclosed therein..
Macau University Of Science And Technology


10/29/15
20150307464 

Therapeutic thiazolidinone compounds


Thiazolidinone compounds, including pharmaceutically acceptable salts of the compounds, are cetp inhibitors and are useful for raising hdl-cholesterol, reducing ldl-cholesterol, and for treating or preventing atherosclerosis.. .
Merck Sharp & Dohme Corp.


10/29/15
20150306123 

Use of ivermectin and derivatives thereof


The present invention relates to the new use of antiparasitic agents, such as ivermectin, abamectin/avermectin, doramectin and so on, and the design method of the derivatives for the new use. The said compounds including macrolide abamectin/avermectin, ivermectin, doramectin and the derivatives thereof, may be used in the manufacture of a medicament for use in treating metabolic related diseases in a mammal, such as hyperglycemia, insulin resistance, hypertriglyceridemia, hypercholesterolemia, diabetes, obesity, etc, and famesoid x receptor mediated diseases, such as cholestasia, gallstone, non alcohol fatty liver disease, atherosclerosis, inflammation, cancer, etc..
Roivant Hepatology Ltd.


10/29/15
20150306060 

Method for the treatment of hypercholesterolemia


Disclosed is a therapeutic management method of hypercholesterolemia in mammals. More specifically, the present invention relates to a method of reducing high levels of circulating cholesterol (hypercholesterolemia) in the blood stream of mammals, said method involving step of administering therapeutically effective amounts of calebin a to said mammals to bring about the effects of (i) reducing the amount of total blood cholesterol levels; (ii) reducing the concentrations of low density lipoproteins (ldl) and very low density lipoproteins (vldl); (iii) increasing the concentrations of high density lipoproteins (hdl) and (iv) reducing concentrations of serum triglycerides..

10/29/15
20150306059 

Method for the treatment of hypercholesterolemia


Disclosed is a therapeutic management method of hypercholesterolemia in mammals. More specifically, the present invention relates to a method of reducing high levels of circulating cholesterol (hypercholesterolemia) in the blood stream of mammals, said method involving step of administering therapeutically effective amounts of calebin a to said mammals to bring about the effects of (i) reducing the amount of total blood cholesterol levels; (ii) reducing the concentrations of low density lipoproteins (ldl) and very low density lipoproteins (vldl); (iii) increasing the concentrations of high density lipoproteins (hdl) and (iv) reducing concentrations of serum triglycerides..

10/22/15
20150297676 

Composition comprising grim-19 as active ingredient for preventing or treating obesity or lipid-related metabolic diseases


The present invention relates to a composition comprising grim-19 protein as an active ingredient for preventing or treating obesity or lipid-related metabolic diseases. More particularly, the present invention relates to a composition for preventing or treating obesity or lipid-related metabolic diseases wherein the composition comprises grim-19 protein as an active ingredient for preventing or treating metabolic diseases caused by immune response disorders or interactions between genetic, metabolic, or environmental complex factors.
Catholic University Industry Academic Cooperation Foundation


10/15/15
20150291563 

4,5-dihydro-1h-pyrazole derivative or salts thereof, and pharmaceutical composition comprising same


The present invention provides a 4,5-dihydro-1h-pyrazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The 4,5-dihydro-1h-pyrazole derivative or its pharmaceutically acceptable salt effectively increases the lxr transcriptional activity, and therefore can be usefully applied for preventing or treating a dysfunction in cholesterol metabolism, such as cholesterol gallstone, hyperlipidemia, or coronary atherosclerosis..

10/08/15
20150284474 

Anti-pcsk9 antibodies with ph-dependent binding characteristics


An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hpcsk9) characterized by the ability to reduce serum ldl cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum hdl cholesterol and/or with little or no measurable effect on liver function, as determined by alt and ast measurements.. .

10/08/15
20150284473 

Methods for reducing cardiovascular risk


The present invention provides methods for treating diseases and disorders that are associated with elevated levels of lipids and lipoproteins. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a pcsk9 inhibitor.

10/08/15
20150284471 

Human lcat antigen binding proteins and their use in therapy


Antigen binding proteins that activate lcat are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided.

10/08/15
20150284411 

Novel azabenzimidazole hexahydrofuro[e,2-b]furan derivatives


Novel compounds of the structural formula (i) are activators of amp-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the ampk activated protein kinase. The compounds of the present invention may be useful in the treatment of type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension..

10/08/15
20150284317 

Novel low molecular weight cationic lipids for oligonucleotide delivery


The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver.

10/08/15
20150284316 

Low molecular weight cationic lipids for oligonucleotide delivery


The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver.

10/08/15
20150283236 

Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled


The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a patient a pharmaceutical composition comprising a pcsk9 inhibitor.

10/08/15
20150283202 

Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases


This invention also provides a method to prevent, control, and treat a lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an an inhibitor of cgmp-dependent phosphodieasterases.. .

09/24/15
20150265814 

Devices and methods for controlling dietary lipid uptake


Methods and devices for redirecting at least a portion of a fluid from the mesenteric lymphatic system for elimination from the body are disclosed. The fluid may be redirected for elimination through the urinary system, through the gastrointestinal system, or redirected outside the body.
Boston Scientific Scimed, Inc.


09/24/15
20150265571 

Use of delta tocopherol for the treatment of lysosomal storage disorders


This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of δ tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders.
The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services


09/24/15
20150265570 

Transmucosal delivery of tocotrienol


The present invention relates to pharmaceutical compositions formulated for transmucosal delivery, and in particular sublingual delivery, comprising at least one tocotrienol or derivative thereof together with one or more pharmaceutically acceptable excipients. The present further relates to the use of said compositions for treating or preventing post exercise muscle soreness, delayed onset muscle soreness, cardiac fibrosis, hypertension, inflammation, stroke, cancer, elevated cholesterol and/or triglycerides, baldness, hypertrophy, conditions resulting from radiation exposure, stabilizing and/or controlling blood glucose levels, and improving exercise endurance and capacity..
Gordagen Pharmaceuticals Pty Ltd


09/17/15
20150260631 

System and assessing quanitites or sizes of lipoprotein particles from lipoprotein particle compositions


This invention relates to methods for assessing quantities of spherical or substantially spherical lipoprotein particles or portions thereof present in a biological sample based on the measurement of free cholesterol and/or phospholipid content in the lipoprotein particles. The invention also relates to the use of the assessed quantities of the lipoprotein particles or portions thereof to determine whether a subject is at increased risk for cardiovascular diseases and cardiodiabetes..
Health Diagnostic Laboratory, Inc.


09/17/15
20150258078 

Compositions containing berberine and pantethine and methods for treatment of lipid metabolism disorders


The present invention is directed to compositions incorporating purified herbal ingredients for the treatment of conditions such as hypercholesterolemia, hyperlipidemia, elevated triglycerides, syndrome x (metabolic syndrome), hyperglycemia, diabetes, cardiovascular disease and the like as well as disorders of lipid metabolism with failed response to standard therapies (for example statins) or any other disease or condition associated with lipids and lipid metabolism, as well as methods for their use. The compositions incorporating purified herbal ingredients can incorporate combinations of berberine and pantethine, alone or with one or more of chromium polynicotinate or chromium picolinate, biotin, curcumin and/or bioperin..

09/10/15
20150251999 

Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid


Novel salt forms of [r—(r*,r*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid characterized by their x-ray powder diffraction pattern and solid-state nmr spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and alzheimer's disease.. .
Pfizer Inc.


09/10/15
20150250850 

Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome


The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject.
Vanderbilt University


09/10/15
20150250841 

Methods and compositions to reduce fat gain, promote weight loss in animals


The present disclosure relates to compositions and related methods to reduce body weight, body fat, waist and hip size, plasma total cholesterol, ldl, triglycerides, blood glucose, leptin and c-reactive protein levels and increase in hdl and serotonin levels in an mammal. The lepticore® formulation disclosed, at both the low and high dosages, is helpful in the management of fat gain and its related complications.

09/10/15
20150250840 

Medicinal composition of extract of seed of emblica officinalis and preparing the same


A composition having an extract of seed of emblica officinalis. Methods of preparing extract of seed of emblica officinalis.

09/10/15
20150250835 

Composition and lactobacillus reuteri gmnl-89 in treating type 2 diabetes


Present invention features a novel use of lactobacillus for treating type 2 diabetes, wherein the lactobacillus is lactobacillus reuteri gmnl-89 with the deposition numbers of bcrc 910340 and cctcc m 207154 and comprises of live, dead bacteria or supernatant of the bacterial culture(s) and a pharmaceutically acceptable vehicle. The invention also discloses the efficacies of the indicated lactobacillus strain including anti-oxidative enzyme activity, anti-inflammation, reduction of blood glucose level, reduction of triglycerides, reduction of total cholesterol, reduction of ldl, increase of hdl and improve insulin utilization..
Genmont Biotech Inc.


09/10/15
20150250802 

Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm


Novel methods for prevention, reduction or elimination of the incidence of male androgen deficiency symptoms or diseases including male hypogonadism-associated symptoms and diseases associated with low serum testosterone and/or low dhea or low total androgens in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (dhea) and a selective estrogen receptor modulator (serm) (particularly acolbifene), an antiestrogen or a prodrug of the two. The symptoms or diseases are loss of libido, erectile dysfunction, tiredness, loss of energy, depression, bone loss, muscle loss, muscle weakness, fat accumulation, memory loss, cognition loss, alzheimer's disease, dementia, loss of body hair, fertility problems, insomnia, gynecomastia, anemia, hot flushes, sweats, decreased sense of well-being, obesity, osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, cardiovascular disease and type 2 diabetes.

09/10/15
20150250756 

Methods of treating hypercholesterolemia


In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of treating hypercholesterolemia, comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.. .
Amarin Pharmaceuticals Ireland Limited


09/10/15
20150250724 

Long-lasting, controlled-release local anesthetic liposome preparation


A long-lasting, controlled-release local anesthetic liposome preparation is produced by: providing a liposome composition, which is obtained by mixing, in a water-miscible organic solvent, a first aqueous phase solution with a water-miscible organic solution, in which a phospholipid and cholesterol are contained at a defined total concentration, at a defined ratio by volume thereby obtaining an emulsion wherein a total concentration of the phospholipid and cholesterol in the mixed phase is at 15 w/v % to 50 w/v %, followed by subjecting the emulsion to external solution exchange with a second aqueous phase solution to obtain a liposome composition wherein an ion gradient is formed between an internal-region aqueous phase of a liposome membrane made of the first aqueous phase solution and an external-region aqueous phase of the liposome membrane made of the second aqueous phase solution; and encapsulating a local anesthetic in the internal-region aqueous phase according to a remote loading method.. .
Terumo Kabushiki Kaisha


09/10/15
20150250220 

Nutritional compositions containing ceramide and uses thereof


The present disclosure relates to nutritional compositions that include at least one ceramide. The nutritional compositions may further include galactose, sialic acid, or cholesterol.
Mead Johnson Nutrition Company






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cholesterol for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cholesterol with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.985

5581

2 - 1 - 111